UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 489

Sortiert nach

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Nature communications, 2018-05, Vol.9 (1), p.2126-15, Article 2126

2018

Volltextzugriff (PDF)

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Clinical cancer research, 2017-07, Vol.23 (13), p.3277-3284

2017

Volltextzugriff (PDF)

Urinary Cadmium and Osteoporosis in U.S. Women ≥ 50 Years of Age: NHANES 1988-1994 and 1999-2004

Environmental health perspectives, 2008-10, Vol.116 (10), p.1338-1343

2008

Volltextzugriff (PDF)

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

Proceedings of the National Academy of Sciences - PNAS, 2009-07, Vol.106 (28), p.11697-11702

2009

Volltextzugriff (PDF)

The relationship between body iron stores and blood and urine cadmium concentrations in US never-smoking, non-pregnant women aged 20–49 years

Environmental research, 2011-07, Vol.111 (5), p.702-707

2011

Volltextzugriff (PDF)

Environmental cadmium and breast cancer risk

Aging (Albany, NY.), 2010-11, Vol.2 (11), p.804-814

2010

Volltextzugriff (PDF)

An LC–MS/MS method for simultaneous determination of LB-100 and its active metabolite, endothall, in human plasma

Bioanalysis, 2023-09, Vol.15 (17), p.1095-1107

2023

Volltextzugriff (PDF)

Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma

Journal of neuro-oncology, 2020-06, Vol.148 (2), p.231-244

2020

Volltextzugriff (PDF)

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma

Cancers, 2020-01, Vol.12 (1), p.139

2020

Volltextzugriff (PDF)

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1820-1835

2021

Volltextzugriff (PDF)

Cadmium, follicle-stimulating hormone, and effects on bone in women age 42–60 years, NHANES III

Environmental research, 2010-01, Vol.110 (1), p.105-111

2010

Volltextzugriff (PDF)

Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Molecular cancer therapeutics, 2022-04, Vol.21 (4), p.700-700

2022

Volltextzugriff (PDF)

Environmental cadmium and breast cancer risk

Aging (Albany, NY.), 2010-11, Vol.2 (11), p.804-814

2010

Volltextzugriff (PDF)

Detection of Cancer-Specific Markers Amid Massive Mass Spectral Data

Proceedings of the National Academy of Sciences - PNAS, 2003-12, Vol.100 (25), p.14666-14671

2003

Volltextzugriff (PDF)

Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome

Cell cycle (Georgetown, Tex.), 2009-10, Vol.8 (20), p.3303-3306

2009

Volltextzugriff (PDF)

A phase I study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS2602-TPS2602

2015

Volltextzugriff (PDF)

Abstract LB-193: Protein phosphatase 2A inhibition,with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD1 blockade in a preclinical model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.LB-193-LB-193

2017

Volltextzugriff (PDF)

Abstract 2260: Targeting PP2A with LB100 enhances efficacy of CAIX CAR-T cells against GBM

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2260-2260

2019

Volltextzugriff (PDF)

A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS2636-TPS2636

2014

Volltextzugriff (PDF)

IMMU-55. PHARMACOLOGIC INHIBITION OF PROTEIN PHOSPHATASE-2A, WITH NOVEL INHIBITOR LB-100, ACHIEVES DURABLE IMMUNE-MEDIATED ANTITUMOR ACTIVITY WHEN COMBINED WITH PD1 BLOCKADE

Neuro-oncology (Charlottesville, Va.), 2017-11, Vol.19 (suppl_6), p.vi125-vi125

2017

Volltextzugriff (PDF)

Abstract A175: A phase 1 study of a novel inhibitor of protein phosphatase 2A alone or in combination with docetaxel

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A175-A175

2015

Volltextzugriff (PDF)

Courtship as an honest indicator of male parental quality in the bicolor damselfish, Stegastes partitus

Behavioral ecology, 1991-01, Vol.2 (4), p.295-300

1991

Volltextzugriff (PDF)

A Community and Academic Partnership to Improve Breast Cancer Outcomes for African Americans on Long Island: A Ministry of Health Dissemination

Home health care management & practice, 2006-08, Vol.18 (5), p.361

2006

Volltextzugriff (PDF)

Macroecological reforms as a strategy for reducing educational risks associated with poverty

Journal of education policy, 1998-03, Vol.13 (2), p.167-178

Kovach, John A

1998

Volltextzugriff (PDF)

Abstract 5497: An inhibitor of phosphatase PP2A enhances in vivo anticancer activity of a phospho (ADP-ribosyl) polymerase inhibitor (PARPi) combined with temozolomide (TMZ)

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5497-5497

2011

Volltextzugriff (PDF)

1 – 25 von 489

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(417)
Mit Volltextzugriff
(413)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(278)
Life Sciences & Biomedicine
(247)
Humans
(202)
Female
(132)
Surgery
(117)
Middle Aged
(115)
Male
(99)
Adult
(90)
Aged
(67)
Retrospective Studies
(59)
Biological And Medical Sciences
(58)
Treatment Outcome
(47)
Medical Sciences
(46)
Oncology
(43)
Risk Factors
(35)
Animals
(33)
Postoperative Complications - Epidemiology
(26)
Aged, 80 And Over
(25)
Risk Assessment
(24)
Cardiovascular System & Cardiology
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial

Urinary Cadmium and Osteoporosis in U.S. Women ≥ 50 Years of Age: NHANES 1988-1994 and 1999-2004

Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms

The relationship between body iron stores and blood and urine cadmium concentrations in US never-smoking, non-pregnant women aged 20–49 years

Environmental cadmium and breast cancer risk

An LC–MS/MS method for simultaneous determination of LB-100 and its active metabolite, endothall, in human plasma

Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma

Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Cadmium, follicle-stimulating hormone, and effects on bone in women age 42–60 years, NHANES III

Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer

Environmental cadmium and breast cancer risk

Detection of Cancer-Specific Markers Amid Massive Mass Spectral Data

Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome

A phase I study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

Abstract LB-193: Protein phosphatase 2A inhibition,with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD1 blockade in a preclinical model

Abstract 2260: Targeting PP2A with LB100 enhances efficacy of CAIX CAR-T cells against GBM

A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel

IMMU-55. PHARMACOLOGIC INHIBITION OF PROTEIN PHOSPHATASE-2A, WITH NOVEL INHIBITOR LB-100, ACHIEVES DURABLE IMMUNE-MEDIATED ANTITUMOR ACTIVITY WHEN COMBINED WITH PD1 BLOCKADE

Abstract A175: A phase 1 study of a novel inhibitor of protein phosphatase 2A alone or in combination with docetaxel

Courtship as an honest indicator of male parental quality in the bicolor damselfish, Stegastes partitus

A Community and Academic Partnership to Improve Breast Cancer Outcomes for African Americans on Long Island: A Ministry of Health Dissemination

Macroecological reforms as a strategy for reducing educational risks associated with poverty

Abstract 5497: An inhibitor of phosphatase PP2A enhances in vivo anticancer activity of a phospho (ADP-ribosyl) polymerase inhibitor (PARPi) combined with temozolomide (TMZ)

Suchergebnisse filtern